Straits Times Index
3,241.58 +28.94 (+0.90%) Nikkei
27,476.87 +91.62 (+0.33%) Hang Seng
19,739.42 -176.26 (-0.89%) FTSE 100
7,405.45 -94.15 (-1.26%) Bitcoin USD
27,786.70 +255.89 (+0.93%) CMC Crypto 200
604.07 -14.32 (-2.32%)
GSK plc (GSK.L)
| Previous close | 1,437.80 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 10,053,936 |
| Market cap | 58.877B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 13.22 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.61 (4.26%) |
| Ex-dividend date | 23 Feb 2023 |
| 1y target est | N/A |
- Business Wire
GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
PHILADELPHIA, March 14, 2023--GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
- PR Newswire Asia
Over 90% of adults above the age of 50 carry the virus that causes shingles; yet only 3% of Singaporeans in this age group believe they are at high risk of developing the disease
A GSK-sponsored Ipsos-MORI survey revealed only 3% of Singaporeans aged 50-79 years believe they are at high risk of developing shingles in the next 12 months. The survey among 200 respondents further reported that while 40% believe shingles is serious, only 6% spoke to a healthcare professional (HCP) about protection against the disease.
- PR Newswire Asia
GSK Singapore announces regulatory approval for Nucala (mepolizumab) in two additional eosinophil-driven diseases
GSK Singapore today announced that Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), has been approved for treatment in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and hypereosinophilic syndrome (HES)[1]. These new indications for mepolizumab are for the add-on maintenance treatment of severe CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, and for adult patients with inadequately control
